Franco-Austrian Vaccine Against COVID-19 could "Change the Rules of the Game"

Society » HEALTH | November 11, 2021, Thursday // 12:40
Bulgaria: Franco-Austrian Vaccine Against COVID-19 could "Change the Rules of the Game" GettyImages

With the approval of a contract in Brussels, the vaccine of the European manufacturer Valneva against coronavirus regained the attention that these products initially received, and the company's shares rose.

The European Commission announced yesterday that it had approved the ordering of tens of millions of it only a year after the first contracts for the supply of coronavirus vaccines. Until a few months ago, Brussels and the Franco-Austrian company were arguing over issues such as production capacity. Britain canceled an order for 100 million doses last month due to a dispute over irregularities in the implementation of the contract.

Unlike last winter, the EU has enough vaccines and faces more skepticism from those who have not yet been immunized. However, another vaccine could create new opportunities for a more flexible response against the ever-changing virus. British doctor Amir Khan has suggested that it could "change the game" in the fight against the virus.

 

Why it works differently

Valneva's vaccine is inactivated - it contains a "killed" version of the coronavirus, which can no longer get people sick. This is a proven technique and is the basis of the principle of vaccines against influenza and pomiomelitis.

With this technology, the immune system will recognize the entire virus, not just the spike protein.

Some of the Chinese vaccines developed against the disease have also been inactivated, but they have shown low efficacy, although more data are needed on Valneva's vaccine. In some Balkan countries, where the Sinopharm product (also inactivated) has been approved, comments have been heard that this type of vaccine is more preferred by some of the population because it is better known.

 

Potential solution for mutations

According to the company and some experts, the technology produces a better immune response and increases the number of cells that can remember and recognize different parts of the virus.

Valneva claims that the advantage is the possibility that if mutations in the spike protein occur that make it unrecognizable to the vaccine, the immune response is strong enough to identify other parts of the virus. The mutations that the COVID-19-causing coronavirus SARS-CoV-2 has undergone in recent years are an example of the need to invest in vaccines that do not rely solely on training to recognize part of the virus. The success of this vaccine may be important given the expectation that mutations will continue in an environment where the virus will continue to circulate uncontrollably due to the lack of either restrictions or vaccines, or both.

 

Does it work OK

So far, clinical trials show that in some respects it is better than the Astra Zeneca vaccine. Blood tests of volunteers who received it showed high levels of antibodies, which were formed in 95% of cases.

The company claims that no serious side effects or cases of serious illness have been found in phase III trials among 4,000 people in the UK.

/Dnevnik

We need your support so Novinite.com can keep delivering news and information about Bulgaria! Thank you!

Health » Be a reporter: Write and send your article
Tags: Valneva, inactivated, vaccine, COVID-19

Advertisement
Advertisement
Bulgaria news Novinite.com (Sofia News Agency - www.sofianewsagency.com) is unique with being a real time news provider in English that informs its readers about the latest Bulgarian news. The editorial staff also publishes a daily online newspaper "Sofia Morning News." Novinite.com (Sofia News Agency - www.sofianewsagency.com) and Sofia Morning News publish the latest economic, political and cultural news that take place in Bulgaria. Foreign media analysis on Bulgaria and World News in Brief are also part of the web site and the online newspaper. News Bulgaria